Video AMP 2023

Value of Alternative Access for Treatment of Multilevel and Multivessel Disease

Fadi A. Saab, MD, FASE, FACC, FSCAI

Advanced Cardiac and Vascular Centers, Grand Rapids, Michigan

06/28/2023

In this case, the common nature of CLTI patients with multivessel, multilevel disease and multiple comorbidities is well demonstrated. The use of strategies to reduce contrast and radiation exposure for these patients is very important for success of revascularization. This case highlights the use of these technologies and the importance of staging patients with complex CLI disease.

Join us at the 2023 Amputation Prevention Symposium (AMP), taking place August 16-19 in Chicago, to see similar complex cases performed live by expert operators.

Stay in the Know

Vascular Disease Management Newsletter

News

First Aid guidelines

AHA/American Red Cross: Updated First Aid Guidelines Enhance Care for Opioid Overdose, Bleeding, Other Emergencies

11/14/2024

These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.

These are the first major...

11/14/2024

Cath Lab Digest

Late-Breaking Trials

Final Round of Late-Breaking Clinical Trial Results Announced at VIVA24

11/06/2024

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...

The VIVA Foundation, a...

11/06/2024

Vascular Disease Management

Late-Breaking Trials

Third Round of Late-Breaking Clinical Trial Results Announced at VIVA24

11/05/2024

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...

The VIVA Foundation, a...

11/05/2024

Vascular Disease Management

Late-Breaking Trials

Second Round of Late-Breaking Clinical Trial Results Announced at VIVA24

11/04/2024

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...

The VIVA Foundation, a...

11/04/2024

Vascular Disease Management

Late-Breaking Trials

First Round of Late-Breaking Clinical Trial Results Announced at VIVA24

11/04/2024

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...

The VIVA Foundation, a...

11/04/2024

Vascular Disease Management

Image-Guided Therapy

Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single-Device to Treat Peripheral Artery Disease

11/04/2024

With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...

With a unique world-first...

11/04/2024

Vascular Disease Management

Pulmonary Embolism

Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism

11/04/2024

QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...

QUADRA-PE study will evaluate...

11/04/2024

Vascular Disease Management

Peripheral Arterial Disease

FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease

11/04/2024

MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...

MOUNTAIN VIEW, Calif. – November...

11/04/2024

Vascular Disease Management

Patient Awareness

Baby Boomers Beware: More Americans Than Ever Before Now at Higher Risk for Common Blood Vessel Diseases

10/31/2024

New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...

New survey reveals nearly one in...

10/31/2024

Vascular Disease Management

DCB

SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery

10/30/2024

Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...

Data from the prospective,...

10/30/2024

Cath Lab Digest

Value of Alternative Access for Treatment of Multilevel and Multivessel Disease

Stay in the Know

News

Specialties

Events

Year Round Education

HMP Global Products